A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first‐line therapy for patients with breast cancer (<scp>CBCRT</scp>01)Jianghao Chen, Ling Wang, Meiling Huang et al.|International Journal of Cancer|2017Cited by 30
Downregulation of RIPK4 Expression Inhibits Epithelial-Mesenchymal Transition in Ovarian Cancer through IL-6Yi Huan, Rong Zhang|Journal of Immunology Research|2021Cited by 13
Exosomal miR-543 Inhibits the Proliferation of Ovarian Cancer by Targeting IGF2Shupei Zhang, Yi Huan|Journal of Immunology Research|2022Cited by 12